Chordia Therapeutics Publishes First-in-Human Phase 1 Results of CLK Inhibitor Rogocekib ...

Chordia Therapeutics published Phase 1 clinical trial results of rogocekib, a CLK inhibitor, showing manageable safety and partial responses in solid tumors, particularly ovarian cancer with MYC gene amplification, supporting expansion into solid tumor indications.

This Wire brief sits within Fusion42's coverage of Biotech.